Mature Protein Numbering: P84L


Clinical Phenotype: Hyperlipoproteinemia Type IIa
Reference Assembly: GRCh37/hg19
Position: Chr19:45411858 C>T
Transcript: NM_000041; ENSG00000130203
dbSNP ID: rs11083750
Coding/Non-Coding: Coding
DNA Change: Substitution
Expected RNA Consequence: Substitution
Expected Protein Consequence: Missense
Codon Change: CCG to CTG
Reference Isoform: APOE Isoform 1
Genomic Region: Exon 4


This variant was identified in a French patient in a cohort of nearly 6,000 unrelated individuals with primary dyslipidemia (Abou Khalil et al., 2022). The carrier had elevated low-density lipoprotein (LDL) cholesterol in blood and was diagnosed with autosomal dominant hypercholesterolemia, also known as hyperlipoproteinemia type IIa (HLPP2a). They did not carry mutations in the genes most commonly associated with HLPP2a—LDLR, PCSK9, APOB—but they had a strong probability of their condition being due to variants in multiple genes (weighted polygenic risk scores in decile X). Their APOE genotype was APOE3/E4. Their APOE genotype was APOE3/E4.

The variant was absent from the gnomAD variant database.

Biological Effect

The biological effect of this variant is unknown, but multiple computational algorithms predicted it is damaging, and its PHRED-scaled CADD score (23.4), which integrates diverse information in silico, was above 20, suggesting a deleterious effect (Abou Khalil et al., 2022). Also of note, P102 is an evolutionarily conserved amino acid and two carriers of another substitution at this position, P102R, also suffered from hypercholesterolemia. The authors classified the variant as likely pathogenic.

Last Updated: 05 Dec 2022


No Available Comments

Make a Comment

To make a comment you must login or register.


Mutations Citations

  1. APOE P102R

Paper Citations

  1. . APOE Molecular Spectrum in a French Cohort with Primary Dyslipidemia. Int J Mol Sci. 2022 May 21;23(10) PubMed.

Further Reading

No Available Further Reading

Protein Diagram

Primary Papers

  1. . APOE Molecular Spectrum in a French Cohort with Primary Dyslipidemia. Int J Mol Sci. 2022 May 21;23(10) PubMed.

Other mutations at this position

Disclaimer: Alzforum does not provide medical advice. The Content is for informational, educational, research and reference purposes only and is not intended to substitute for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on Alzforum.